SERUM YKL-40 LEVELS IN CHRONIC HEART FAILURE

Inflammatory processes are involved in the pathogenesis and development of chronic heart disease. The promising novel inflammatory biomarker YKL-40 is related to the degree of inflammation and pathological tissue remodeling. The aim of this study was to determine serum YKL-40 levels in patients with...

Full description

Saved in:
Bibliographic Details
Published inJournal of IMAB Vol. 20; no. 2; pp. 506 - 509
Main Authors Kazakova, Maria, Nikolov, Petar, Simitchiev, Kiril, Nikolov, Fedya, Sarafian, Victoria
Format Journal Article
LanguageEnglish
Published Peytchinski Publishing 27.06.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Inflammatory processes are involved in the pathogenesis and development of chronic heart disease. The promising novel inflammatory biomarker YKL-40 is related to the degree of inflammation and pathological tissue remodeling. The aim of this study was to determine serum YKL-40 levels in patients with chronic heart failure and to evaluate the potential relationship with ultrasonography findings. Forty-three individuals were enrolled in the study – 24 patients (10 females and 14 males) with chronic heart failure, aged 70±11 (mean ± standard deviation) and 16 healthy people as age-matched controls (above 50 years). The serum YKL-40 levels were assessed by ELISA. Sonographic measurements such as two-dimensional, Power wave, Continuous Wave, Colour mode and M-Mode were performed using a diagnostic ultrasound system (PHILIPS Ultrasound, Washington, US) with a L11-3 probe of 3-11 MHz. The six minute walk test was used to assess functional capability of patients. Our study revealed significantly higher serum YKL-40 levels in patients compared to the control group (P=0.010). No relation was found between the glycoprotein and the results from the ultrasonographic and functional examination. We suppose that increased serum YKL-40 levels in patients with chronic heart failure might reflect the inflammatory route in the development of the disease.
ISSN:1312-773X
1312-773X
DOI:10.5272/jimab.2014202.506